<DOC>
	<DOCNO>NCT01691885</DOCNO>
	<brief_summary>The primary objective study test hypothesis lung hyperinflation contribute cardiac dysfunction COPD treatment lung deflation FF/VI Inhalation Powder 100/25 mcg administer daily ( QD ) result reversal cardiac dysfunction compare placebo . This assessed measure right leave global regional systolic diastolic cardiac function assess use 30 minute CMR . A secondary objective investigate effect FF/VI inhalation powder 100/25mcg QD measure arterial stiffness form pulse wave analysis distensability pulmonary systemic circulation .</brief_summary>
	<brief_title>RELOVAIR® Lung Deflation Study</brief_title>
	<detailed_description>This Phase IIIb , randomise , double-blind , placebo-controlled , cross-over , single-centre study investigate acute effect FF/VI inhalation powder 100/25mcg QD lung deflation cardiac biventricular function arterial stiffness adult COPD . Subjects visit clinic minimum 4 time 28-day period contact either telephone contact clinic visit ( Visit/Contact 4 ) . A 7-day run-in period follow two 7-day ( maximum 14-day ) treatment period separate 7 ( ±2 ) day wash-out period . The first dose treatment take day randomisation . A safety Follow-up contact ( either visit telephone ) occur 7 ( ±2 ) day post last treatment day . Subjects prescribed appropriate COPD therapy end Treatment Visit 5 , require . There plan provide study drug compassionate use follow study completion . It plan 44 complete evaluable subject . Subjects withdraw early replace . In order ensure 44 evaluable subject , assume 10 % protocol deviation rate , 49 subject randomise . The total duration subject participation , include follow-up period , approximately 36 day .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Type subject : Outpatient . Informed consent : Subjects must give sign dated write informed consent participate . Gender : Males female . Female subject must postmenopausal use highly effective method avoidance pregnancy . The decision include exclude woman childbearing potential may make discretion investigator accordance local practice relation adequate contraception . Age 40 Smoking history least 15 pack year . Previous smoker define stop smoke least 6 month prior Visit 1 . Established diagnosis COPD accord ATS/ERS criterion : Subjects measure postalbuterol/salbutamol FEV1 le 70 % predict normal value ; FEV1/FVC ratio bronchodilator le 0.7 ; Postbronchodilator spirometry perform approximately 15 minute subject selfadministered 4 inhalation ( i.e. , total 400mcg ) salbutamol via MDI valvedholding chamber . The FEV1/FVC ratio FEV1 percent predict value calculate ; MRC SCORE great 1 Residual Volume ( RVol ) great equal 20 % predict value demonstrate evidence reversibility post bronchodilator great equal 7.5 % predict . Pregnancy : Women pregnant lactating . Asthma : Subjects current diagnosis asthma . ( Subjects prior history asthma eligible also current diagnosis COPD ) . α1antitrypsin deficiency : Subjects know α1 antitrypsin deficiency underlie cause COPD Other respiratory disorder : Subjects active tuberculosis lung cancer well clinically significant bronchiectasis , sarcoidosis , pulmonary fibrosis , interstitial lung disease active pulmonary disease . Pulmonary hypertension cause COPD . Lung resection transplantation : Subjects lung volume reduction surgery within 12 month prior Screening lung transplant pneumonectomy . A moderate/severe COPD exacerbation resolve least 14 day prior screen least 30 day follow last dose oral corticosteroid ( applicable ) . Lower respiratory tract infection : Subjects low respiratory tract infection require use antibiotic within 6 week prior screen . Pulmonary Rehabilitation : Patients exclude acute phase pulmonary rehabilitation 4 week prior screen Current severe heart failure ( New York Heart Association class IV ) [ New York HeartAssociation , 1994 ] . Subjects also exclude know ejection fraction le 30 % . Abnormal clinically significant 12lead ECG Other systemic inflammatory condition associate chronic inflammation opinion investigator ( e.g . rheumatoid arthritis , connective tissue disorder Inflammatory Bowel Disease ) Other significant disease / abnormality : Any lifethreatening condition life expectancy great 1 year , vascular disease COPD , might prevent subject complete study . Coronary Artery Bypass Grafting ( CABG ) 6 month prior screen . Myocardial infarction , cerebrovascular event coronary artery intervention CABG 1 month prior screen . Inclusion patient event 1 month prior screen base physician 's judgment . History malignancy within past 5 year , nonmelanoma skin cancer . End stage chronic renal disease : Subjects exclude renal replacement therapy ( hemodialysis peritoneal ) . Drug/food allergy : Subjects history hypersensitivity study medication ( e.g . betaagonists , corticosteroid ) component inhalation powder ( e.g . lactose , magnesium stearate ) . In addition , patient history severe milk protein allergy , opinion study physician , contraindicate subject 's participation also exclude . Drug/alcohol abuse : Subjects know suspected history alcohol drug abuse within last 2 year . Oxygen therapy : Subjects receive treatment longterm oxygen therapy ( LTOT ) nocturnal oxygen therapy require great 12 hour day . Oxygen initiate trial . Questionable validity consent : Subjects history psychiatric disease , intellectual deficiency , poor motivation condition limit validity inform consent participate study potential compliance study procedure . Additional medication : Use investigational device investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Use following medication permit within follow timeframes : Prohibited Treatment : Depot corticosteroid , Time : 12 week ; Prohibited Treatment : Cytochrome P450 3A4 strong inhibitor include limited antiretrovirals ( protease inhibitor ) ( e.g. , indinavir , nelfinavir , ritonavir , saquinavir , atazanavir ) ; imidazole triazole anti fungals ( e.g. , ketaconazole , itraconazole , voriconazole ) ; clarithromycin , telithromycin , troleandomycin , mibefradil , cyclosporin , nefazodone , Time : 6 week , Grapefruit allow Visit 1 , limit one glass grapefruit juice ( 250 mL/8 ounce ) one grapefruit per day ( The use cytochrome p450 3A4 inhibitor inducer presence significant liver impairment result participant exclude trial ) ; Prohibited Treatment : Systemic , oral , parenteral ( intraarticular ) corticosteroid , Time : 30 day ; Prohibited Treatment : Antibiotics , Time : 6 week ; Prohibited Treatment : Inhaled corticosteroid , Time : 2 week ; Inhaled ICS/LABA combination product , Time : 2 week ; Prohibited Treatment : Longacting anticholinergic ( e.g. , tiotropium ) , Time : 4 day ; Prohibited Treatment : PDE4 inhibitor ( e.g. , roflumilast ) , Time : 1 week ; Prohibited Treatment : Oral leukotriene inhibitor ( e.g. , zafirlukast , montelukast , zileuton ) , Time : 48 hour ; Prohibited Treatment : Inhaled long act beta2agonists ( LABA ) ( e.g. , salmeterol ) , Time : 48 hour ; Prohibited Treatment : Oral betaagonists , Time : 48 hour ; Prohibited Treatment : Inhaled sodium cromoglycate nedocromil sodium , Time : 24 hour ; Prohibited Treatment Ipratropium/albuterol ( salbutamol ) combination product , Time : 6 hour ; Prohibited Treatment : Shortacting anticholinergic ( e.g. , ipratropium bromide ) , Time : 6 hour ( ipratropium supply rescue study , inhale nebulized form ) ; Prohibited Treatment : Theophylline preparation , Time : 48 hour ; Prohibited Treatment : Inhaled shortacting beta2agonists , Time : 6 hour ( albuterol/salbutamol supply rescue study , inhale nebulized form )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>